Paper40568833
Sorafenib with or without co-interventions for hepatocellular carcinoma.
Chen S and 4 others. Cochrane Database Syst Rev, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Sorafenib with or without co-interventions for hepatocellular carcinoma. Papers, record 40568833. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40568833
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Sorafenib | Major topic |
| Adult | |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Systematic Reviews as Topic |
Source PubMed
References169
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33640712 | Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo. | Pathol Res Pract | 2021 | https://conductscience.org/library/papers/33640712 | PubMed |
| 2 | 34200809 | Is the Concurrent Use of Sorafenib and External Radiotherapy Feasible for Advanced Hepatocellular Carcinoma? A Meta-Analysis. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34200809 | PubMed |
| 3 | 34680278 | In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play? | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34680278 | PubMed |
| 4 | 11776102 | Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma. | Chin Med J (Engl) | 2000 | https://conductscience.org/library/papers/11776102 | PubMed |
| 5 | 29712486 | Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. | Future Oncol | 2018 | https://conductscience.org/library/papers/29712486 | PubMed |
| 6 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 7 | 31421157 | Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. | J Hepatol | 2019 | https://conductscience.org/library/papers/31421157 | PubMed |
| 8 | 28983565 | The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28983565 | PubMed |
| 9 | 25260315 | Liver resection for HCC: patient's selection and controversial scenarios. | Best Pract Res Clin Gastroenterol | 2014 | https://conductscience.org/library/papers/25260315 | PubMed |
| 10 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 11 | 23715941 | Sorafenib: from literature to clinical practice. | Ann Oncol | 2013 | https://conductscience.org/library/papers/23715941 | PubMed |
| 12 | 29327594 | Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. | Cancer Control | 2018 | https://conductscience.org/library/papers/29327594 | PubMed |
| 13 | 35999370 | Thermal ablation versus hepatic resection for colorectal cancer with synchronous liver metastases: a propensity score matching study. | Eur Radiol | 2022 | https://conductscience.org/library/papers/35999370 | PubMed |
| 14 | 25223462 | Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. | Oncologist | 2014 | https://conductscience.org/library/papers/25223462 | PubMed |
| 15 | 31801872 | Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. | Gut | 2020 | https://conductscience.org/library/papers/31801872 | PubMed |
| 16 | 30342970 | Increased risks for random errors are common in outcomes graded as high certainty of evidence. | J Clin Epidemiol | 2019 | https://conductscience.org/library/papers/30342970 | PubMed |
| 17 | 23474115 | Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3. | Int J Radiat Oncol Biol Phys | 2013 | https://conductscience.org/library/papers/23474115 | PubMed |
| 18 | 34112190 | A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. | World J Surg Oncol | 2021 | https://conductscience.org/library/papers/34112190 | PubMed |
| 19 | 36737488 | Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis. | Clin Exp Med | 2023 | https://conductscience.org/library/papers/36737488 | PubMed |
| 20 | 19095497 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19095497 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42774851 | Sorafenib-loaded porphyrin-phospholipid liposomes for enhanced chemophototherapy in hepatocellular carcinoma. | RSC Adv | 2026 | https://conductscience.org/library/papers/42774851 | PubMed |
| 42350821 | Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis-hepatocellular carcinoma. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42350821 | PubMed |
| 42327777 | Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42327777 | PubMed |
| 41991725 | The tumor suppressor NDRG2 promotes ACC1 proteasomal degradation and inhibits de novo lipogenesis in hepatocellular carcinoma. | Mol Biomed | 2026 | https://conductscience.org/library/papers/41991725 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40568833
GET https://conductscience.org/api/papers/v1/40568833/references?page=2